WO2010086617A2 - Treatment - Google Patents
Treatment Download PDFInfo
- Publication number
- WO2010086617A2 WO2010086617A2 PCT/GB2010/000153 GB2010000153W WO2010086617A2 WO 2010086617 A2 WO2010086617 A2 WO 2010086617A2 GB 2010000153 W GB2010000153 W GB 2010000153W WO 2010086617 A2 WO2010086617 A2 WO 2010086617A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- cells
- phosphoantigen
- tularemia
- infection
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 34
- 238000011321 prophylaxis Methods 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 38
- 208000034784 Tularaemia Diseases 0.000 claims description 30
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- YKAYCWPQDPILSA-UHFFFAOYSA-N bromohydrin pyrophosphate Chemical compound BrCC(O)(C)CCOP(O)(=O)OP(O)(O)=O YKAYCWPQDPILSA-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 37
- 241000589602 Francisella tularensis Species 0.000 abstract description 10
- 241000589601 Francisella Species 0.000 abstract description 3
- 229940118764 francisella tularensis Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 36
- 239000002671 adjuvant Substances 0.000 description 27
- 238000009472 formulation Methods 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 20
- 239000002502 liposome Substances 0.000 description 19
- 244000052769 pathogen Species 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000000556 agonist Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 229930182490 saponin Natural products 0.000 description 9
- 150000007949 saponins Chemical class 0.000 description 9
- 235000017709 saponins Nutrition 0.000 description 9
- 239000007789 gas Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000002689 Toll-like receptor Human genes 0.000 description 7
- 108020000411 Toll-like receptor Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229930182558 Sterol Natural products 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- 150000003432 sterols Chemical class 0.000 description 6
- 235000003702 sterols Nutrition 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- -1 isopentenyl Chemical group 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 229940126575 aminoglycoside Drugs 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 4
- 239000007764 o/w emulsion Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- RASMOUCLFYYPSU-UHFFFAOYSA-N 2-amino-5-(3,4-dimethoxyphenyl)-6-methylpyridine-3-carbonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(C#N)=C(N)N=C1C RASMOUCLFYYPSU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001092142 Molina Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 201000008246 pneumonic tularemia Diseases 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- AJPADPZSRRUGHI-RFZPGFLSSA-N 1-deoxy-D-xylulose 5-phosphate Chemical compound CC(=O)[C@@H](O)[C@H](O)COP(O)(O)=O AJPADPZSRRUGHI-RFZPGFLSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IJFVSSZAOYLHEE-UHFFFAOYSA-N 2,3-di(dodecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020094 Hilar lymphadenopathy Diseases 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000219287 Saponaria Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000255628 Tabanidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229940099412 Toll-like receptor 2 agonist Drugs 0.000 description 1
- 229940123560 Toll-like receptor 4 agonist Drugs 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 229940122089 Toll-like receptor 8 agonist Drugs 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 201000010324 gastrointestinal tularemia Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XQFCONVZHYBBOH-UHFFFAOYSA-N hippeastidine Chemical compound C1C2=CC(OC)=C(OC)C(O)=C2C23CCC(OC)CC3N1CC2 XQFCONVZHYBBOH-UHFFFAOYSA-N 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000013546 insoluble monolayer Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006148 magnetic separator Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000008311 oculoglandular tularemia Diseases 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present disclosure relates to phosphoantigens for use in the treatment and/or prophylactic protection against tularemia and pharmaceutical compositions comprising said phosphoantigen for the same.
- Francisella tularensis is a small pleomorphic Gram negative coccobacillus which causes the disease tularemia.
- Tularemia is a zoonotic infection. It circulates in populations of rodents and lagomorphs, and outbreaks in humans often parallel outbreaks in animal populations. However, it is not clear whether these animal species are the true reservoir of the bacterium in the environment.
- a wide range of arthropod vectors have been implicated in the transmission of tularemia between mammalian hosts including mosquitoes, ticks, and deer flies. These vectors can also transmit the pathogen to man.
- F. tularensis can also be acquired by contact with, or ingestion of. contaminated material including food and water, and by inhalation of infectious particles.
- F. tularensis subspecies tularensis and holarctica cause the majority of reported cases, with subspecies tularensis causing the more severe disease of the two.
- tularemia can be a severely debilitating or even fatal disease, especially when caused by F. tularensis subspecies tularensis, many cases of disease caused by lower virulence strains are undiagnosed due to the non-specific nature of the symptoms.
- the incubation period is 3-5 days normally (range 1 -21 ), and patients develop flu-like symptoms which may be protracted and relapsing if untreated.
- Symptoms can be variable and depend on the virulence of the strain involved. Infection with the most highly virulent strains can have a case fatality rate of up to 30% if untreated, but antibiotic therapy has reduced this to around 2%. Presentation can range from a mild pneumonia to an acute infection with high fever, malaise, chills, cough, delirium and pulse-temperature dissociation. Radiological examination may reveal parenchymal infiltrates, most commonly in one lobe, and hilar lymphadenopathy may be present. The infectious dose required to cause disease by this route is very low.
- Tularemia responds well to antibiotic therapy. As described above, the mortality rate of the more acute forms of the disease is reduced significantly if the patient receives suitable antibiotics.
- aminoglycosides have been drugs of choice. Although cl inically effective, streptomycin is rarely used now due to problems of ototoxicity and nephrotoxicity. Similarly, although chloramphenicol has been used historically for treatment, it would be unlikely to be used as a first choice due to the possibil ity of irreversible effects on haematopoiesis.
- Gentamicin is a suitable alternative aminoglycoside, and has been used for treatment of pneumonic tularemia.
- tetracyclines Due to the requirement for parenteral dosing and monitoring of serum levels, aminoglycosides are now only used for the most serious cases.
- the tetracyclines have been associated with high relapse rates on withdrawal.
- Doxycycline is effective in treatment of tularemia, but should be avoided for use in young children due to possible effects on developing teeth.
- Ciprofloxacin has been shown to be highly effective in oral therapy of tularemia, and can be considered the current drug of choice for uncomplicated tularemia. It has shown to be effective in treating tularemia in children, and may be suitable for use in pregnant women.
- LVS live vaccine strain
- the present disclosure provides a phosphoanligen for the prophylaxis and/or treatment of tularemia.
- phosphoantigens have been suggested previously as potential adjuvants, there has been no suggestion that such compounds can be used in the treatment of a patient in their own right, that is, it has not been previously suggested that a treatment against any of the pathogens described herein could involve a phosphoantigen in the absence of an antigen, or if an antigen is present, that the antigen is not pharmaceutically active in the prophylaxis and/or treatment of tularemia, or it is not present in sufficient amounts to be pharmaceutically active in the prophylaxis and/or treatment of tularemia.
- adjuvant refers to a non- antigenic substance or substantially non-antigenic substance that is used in combination with an antigen for enhancing the immune response against the antigen.
- treatment can mean prophylactic treatment (i.e. pre-lieating) or treatment post-infection with a pathogen of the type disclosed herein. A treatment is considered successful if the symptoms of an infection are ameliorated or prevented.
- pharmaceutically active means a substance that has a statistically significant measureablc effect on the material/host to which is administered.
- antigen specific to the pathogen refers to an attenuated or avirulent strain of the pathogen or a subunit of the said pathogen that is peculiar to that particular type of pathogen.
- a phosphoantigcn for use in the treatment or prophylaxis of F. tularensis including subspecies thereof such as tularensis.
- a method of treating a patient in need thereof comprising administering a therapeutically effective amount of a phosphoantigen.
- a phosphoantigcn for the manufacture of a medicament for the treatment of infection with F. tularensis.
- Phosphoantigens are small molecular weight molecules with phosphorylated structures that selectively activate human or non-human primate T cells expressing V ⁇ 9V ⁇ 2 T cell receptor.
- Phosphoantigens have been isolated from bacterial species such as TUBag l -4 from M. tuberculosis. Certain other phosphoanligens are known such as BrHPP and IHPP examples 1 and 2 respectively in US application publication No. 2004/0087555. The application relates to compounds of the following formula:
- X is a halogen selected from I, Br or Cl
- R 1 is selected from methyl and ethyl
- Cat + is a cation
- n is an integer between 2 and 20.
- R3 is selected from:
- a particularly potent phosphoaiitigcn is CHDMAPP:
- CaL+ represents one or more cations m is an integer 1 to 3.
- B is O, NH, CHF, CFT or CHi or any other isostcric group, W is C-R6 or N,
- R7 is a C I - I alky! group or any other isosteric group such as CF ⁇ ,
- Any suitable phosphoantigen may be employed to for the prophylaxis or treatment of tularemia, including a synthetic and/or natural phosphoantigen.
- Particularly suitable phosphoantigens arc described above, such as CHDMAPP and IPP, which appear to be very suitable for the treatment of tularemia.
- Prophylaxis as employed herein is intended to refer to wherein an individual has a reduced risk of infection i.e. invasion and/or multipl ication with the relevant pathogen compared to an individual who has not had any prophylactic treatment against the relevant pathogen.
- Reduced risk refers to a 20. 30. 40, 50, 60, 70, 80% or more reduced risk of developing the infection or a severe form thereof (such as developing the infection).
- the phosphoantigcns employed arc not compounds of the following formula:
- X is a halogen selected from I, Br or Cl
- R 1 is selected from mcthy and ethyl
- Cat + is a cation
- n is an integer between 2 and 20.
- the phosphoanligen is employed in combination with a cytokine, for example human recombinant inteiieukin-2 (IL-2) which may be co-administered or co-formulated with the phosphoantigcn.
- a cytokine for example human recombinant inteiieukin-2 (IL-2) which may be co-administered or co-formulated with the phosphoantigcn.
- IL-2 human recombinant inteiieukin-2
- the phosphoantigen or formulation thereof for example as defined herein, may be employed in combination with an antibiotic treatment, for example selected from aminoglycosides, gentamicin. chloramphenicol, doxycyclinc and ciprofloxacin, particularly ciprofloxacin.
- an antibiotic treatment for example selected from aminoglycosides, gentamicin. chloramphenicol, doxycyclinc and ciprofloxacin, particularly ciprofloxacin.
- the disclosure provides a method of treating tularemia comprising administering a therapeutically effective amount of the phosphoantigen prophylactically or to a patient infected by F. lularensis.
- Innoculation or exposure to the relevant pathogen in the environment is not prophylaxis or treatment with an antigen specific to the pathogen, as employed herein.
- the phosphoantigen is administered before infection, for example 1 . 2 or 3 days or a week or a month before exposure.
- the phosphoanligen in given shortly after exposure, inoculation or infection, for example I hour to 3 days, such as 2 to 24 hours after.
- the phosphoantigen is administered before exposure and shortly after exposure, for example as per the time frames above. In one embodiment lhe phosphoantigen is employed for the treatment of chronic infection of tularemia.
- the in vitro data with the relevant pathogens indicates that the bacterial load in a human monocytic cell line is reduced 10 to 100 fold in the presence of human blood or purified ⁇ T cells treated with phosphoantigen and human recombinant IL-2 ex vivo. Given that the cells employed in the in vitro assay are retrieved from the blood of healthy individuals' significant confidence can be gained that the phosphoantigcns will work by the same mechanism in vivo.
- the disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising phosphoantigen in the presence or absence of IL-2, along with a pharmaceutically acceptable excipient for the treatment or prophylaxis of F. tularensis infection.
- the composition may be employed as described above for the phosphoantigen.
- the phosphoantigen is employed in combination with IL-2 and/or a further cytokine such as IL- 15, IL-21 , interferon- ⁇ and/or interferon- ⁇ .
- the active components of the combinations of the disclosure may, for example, be co- formulated if they arc stable when mixed together.
- the components may be formulated separately and co-administcrcd. that is administered at the same time or approximately the same time, for example one immediately after the other.
- the components may be administered sequentially, that is to say with a delay between the administration of each component, for example a delay of I to 1 2 hours.
- the phosphoantigens or compositions according to the present disclosure maybe administered orally, topically, parenterally, transdermal Iy, as a suppository or by any other pharmaceutically appropriate route.
- Typical delivery routes include parenteral administration, e.g., intradermal, intramuscular or by subcutaneous delivery.
- Other routes include oral administration, intranasal, intravaginal routes, intradermal and transdermal administration.
- the phosphoantigen according to the disclosure is provided optionally in cither as a lyophilizcd formulation for rcconstitution later or as a liquid formulation.
- Transdermal administration such as by iontophoresis, may also be an effective method to deliver phosphoanligen to muscle. Epidermal administration may also be employed. Thus the disclosure also extends to delivery by a transdermal patch, which may be occlusive or non- occlusivc.
- the actives can also be formulated for administration via the nasal passages.
- Formulations suitable for nasal administration wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 10 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Suitable formulations wherein the earner is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebulizer include aqueous or oily solutions of the active ingredient.
- compositions of use in the disclosure include liquid preparations, for an orifice, e.g., oral. nasal, anal, vaginal, etc. administration, such as suspensions, syrups or elixirs: and. preparations for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration (e.g., injectable administration) such as sterile suspensions or emulsions.
- compositions of the disclosure the relevant active ingredient may be in admixture with a suitable earner, diluent, or cxcipicnt such as sterile water, physiological sal ine, glucose or the like.
- the active ingredients can be incorporated, if desired, into l iposomes, microspheres or other polymer matrices (Feigner el al., U.S. Pat. No. 5,703,055; Gregoriadis, Liposome
- Liposomes for example, which consist of phospholipids or other lipids, arc nontoxic. physiologically acceptable and mctabolizablc carriers that arc relatively simple to make and administer.
- Liposome carriers may serve to target a particular tissue or infected cells, as well as increase the half-life of the active. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the vaccine to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to. e.g., a receptor prevalent among lymphoid cells, such as monoclonal antibodies, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired immunogen of the disclosure can be directed to the site of lymphoid cells, where the liposomes then deliver the immunogcn(s).
- Liposomes may be formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol.
- the selection of lipids is generally guided by consideration of. e.g., liposome size, acid lability and stability of the liposomes in the blood stream.
- a variety of methods are available for preparing liposomes, as described in. e.g.. Szoka. et al... Ann. Rev. Biophys. Bioeng. 9:467 ( 1980).
- the liposomes generally contain a neutral lipid, for example phosphatidylchol ine, which is usually non-crystalline al room temperature, for example egg yolk phosphatidylcholine, dioleoyl phosphatidylcholine or dilauryl phosphatidylcholine.
- a neutral lipid for example phosphatidylchol ine, which is usually non-crystalline al room temperature, for example egg yolk phosphatidylcholine, dioleoyl phosphatidylcholine or dilauryl phosphatidylcholine.
- the formulation may comprise an adjuvant, for example a known adjuvant formulation may be used to reconstitute the formulation.
- Phosphoantigens employed in die disclosure may be mixed or adsorbed with adjuvants, which include but arc not limited to alum, muramyl dipcptidc and saponins such as Quil A. This may further boost the immune system's ability to deal with the infection.
- Particular adjuvants are those selected from the group of metal salts, oil in water emulsions.
- Toll like receptors agonist (in particular Toll like receptor 2 agonist, Toll l ike receptor 3 agonist, Toll like receptor 4 agonist, Toll like receptor 7 agonist, Toll like receptor 8 agonist and Toll like receptor 9 agonist), saponins or combinations thereof.
- the level of free antigen in a given formulation may be increased by. for example, formulating the composition in the presence of phosphate ions, such as phosphate buffered saline, or by increasing the ratio of antigen to metal salt.
- the adjuvant does not include a metal salt as sole adjuvant.
- the adjuvant does not include a metal salt.
- the adjuvant is a Toll like receptor (TLR) 4 ligand, for example an agonist such as a lipid A derivative, in particular monophosphoryl lipid A or more specifically 3- deacylated monophoshoryl lipid A (3D-MPL).
- TLR Toll like receptor
- 3-Deacylated monophosphoryl lipid A is known from US patent No. 4,912,094 and UK patent application No. 2,220.2 1 1 (Ribi) and is available from Ribi Immunochcm, Montana, USA.
- 3D-MPL is sold under the trademark MPL® by Corixa Corporation and primarily promotes CD4+ T cell responses with an IFN-g (Th 0 phenotype. It can be produced according to the methods disclosed in GB 22202 1 1 A. Chemically it is a mixture of 3-dcacylatcd monophosphoryl lipid A with 3, 4, 5 or 6 acylatcd chains. Generally in the compositions of the present disclosure small particle 3D-MPL is used. Small particle 3D-MPL has a particle size such that it may be sterile- filtered through a 0.22 ⁇ m filter. Such preparations are described in International Patent Application No. WO 94/21292.
- Synthetic derivatives of lipid A arc known and thought to be TLR 4 agonists including, but not limited to:
- 3D-MPL typically when 3D-MPL is used the antigen and 3D-MPL arc delivered with alum or presented in an oil in water emulsion or multiple oil in water emulsions.
- the incorporation of 3D-MPL is advantageous since it is a stimulator of effector T-ccll responses.
- the 3D-MPL may be formulated as liposomes.
- Other TLR4 ligands which may be used are alkyl GIucosaminide phosphates (AGPs) such as those disclosed in WO 98/50399 or US 6303347 (processes for preparation of AGPs are also disclosed), or pharmaceutically acceptable salts of AGPs as disclosed in LJS 6764840.
- Some AGPs are TLR4 agonists, and some are TLR4 antagonists. Both are thought to be useful as adjuvants.
- Quil A is a saponin preparation isolated from the South American tree Quilaja Saponaria Molina and was first described as having adjuvant activity by Dalsgaard ct al. in 1974 ("Saponin adjuvants", Archiv. fur dieumble Virusforschung, Vol. 44, Springer Verlag, Berlin, p243- 254). Purified fragments of Quil A have been isolated by HPLC which retain adjuvant activity without the toxicity associated with Quil A (EP 0 362 278), for example QS7 and QS2 J (also known as QA7 and QA21 ).
- QS2 I is a natural saponin derived from the bark of Quillaja saponaria Molina which induces CD8+ cytotoxic T cells (CTLs), Thi cells and a predominant IgG2a antibody response.
- CTLs cytotoxic T cells
- QS2 I which further comprise a sterol (WO 96/33739).
- the ratio of QS21 : sterol will typically be in the order of 1 : 100 to 1 : 1 weight to weight.
- the ratio of QS2 1 :stcrol being at least 1 :2 w/w.
- QS2 I and sterol will be present in a vaccine in the range of about 1 ⁇ g to about 100 ⁇ g. such as about I O ⁇ g to about 50 ⁇ g per close.
- a formulation comprising QS2 I and liposomes may be prepared, for example containing a charged lipid, which increases the stability of the lipsomc-QS2 l structure for liposomes composed of saturated lipids.
- the amount of charged l ipid is oflen 1 -20% w/w. such as 5- 10%.
- the ratio of sterol Io phospholipid is 1 -50% (mol/mol), such as 20-25%.
- These compositions may contain MPL (3-deacylated mono-phosphoryl l ipid A. also known as 3D-MPL).
- the saponins may be separate in the form of micelles, mixed micelles (generally, but not exclusively with bile salts) or may be in the form of ISCOM matrices (EP 0109942), liposomes or related colloidal structures such as worm-like or ring-like multimeric complexes or lipidic/layered structures and lamellae when formulated with cholesterol and lipid, or in the form of an oil in water emulsion (for example as in WO 95/17210).
- the saponins may often be associated with a metallic salt, such as aluminium hydroxide or aluminium phosphate (WO 98/ 15287).
- the saponin is presented in the form of a l iposome, ISCOM or an oil in water emulsion.
- Immunostimulatory oligonucleotides may also be used.
- oligonucleotides for use in adjuvants of the present disclosure include CpG containing oligonucleotides, generally containing two or more dinucleotide CpG motifs separated by at least three, more often at least six or more nucleotides.
- a CpG motif is a cylosine nucleotide followed by a guanine nucleotide.
- the CpG oligonucleotides are typically deoxynucleotides.
- the internucleotide in the oligonucleotide is phosphorodithioatc, or more preferably a phosphorothioate bond, although phosphodiester and other internucleotide bonds are within the scope of the disclosure.
- oligonucleotides with mixed inlei nucleotide linkages are included within the scope of the disclosure. Methods for producing phosphorothioate oligonucleotides or phosphorodilhioate are described in US5.666. 153, US5,278,302 and WO 95/26204.
- oligonucleotides are as follows: TCC ATG ACG TTC CTG ACG TT (CpG 1826)
- sequences may contain phosphorothioate modified internucleotide linkages.
- Alternative CpG oligonucleotides may comprise one or more sequences above in that they have inconsequential deletions or additions thereto.
- the CpG oligonucleotides may be synthesized by any method known in the art (for example see EP 468520). Conveniently, such oligonucleotides maybe synthesized utilising an automated synthesizer.
- TLR 2 agonist examples include pcptidoglycan or lipoprotein.
- Iinidazoquinolincs such as Imiquimod and Rcsiquimod arc known TLR7 agonists.
- Single stranded RNA is also a known TLR agonist (TLR8 in humans and TLR7 in mice), whereas double stranded RNA and poly IC (polyinosinic-polycytidylic acid - a commercial synthetic mimetic of viral RNA) are exemplary of TLR 3 agonists.
- 3D-MPL is an example of a TLR4 agonist whilst CpG is an example of a TLR9 agonist.
- an immunostimulant may alternatively or in addition be included.
- this immunostimulanl will be 3-deacylated monophosphoryl lipid A (3D-MPL).
- Adjuvants combinations include 3D-MPL and QS2 I (EP 0 671 948 Bl), oil in water emulsions comprising 3D-MPL and QS21 (WO 95/ 17210, WO 98/56414), or 3D-MPL formulated with other carriers (EP 0 689 454 Bl) including liposomes.
- Other adjuvant systems comprise a combination of 3D-MPL, QS2 I and a CpG oligonucleotide as described in US 6558670 and US 6544518.
- the adjuvant comprises 3D-MPL. In one aspect the adjuvant comprises QS2 1 . In one aspect the adjuvant comprises CpG. In one aspect the adjuvant comprises QS2 I and 3D-MPL. In one aspect the adjuvant comprises QS21 , 3D-MPL and CpG
- the adjuvant is formulated as an oil in water emulsion. In one aspect the adjuvant is formulated as liposomes.
- the amount of 3D-MPL used is generally small, but depending on the vaccine formulation may be in the region of 1 to l OOO ⁇ g per dose, generally 1 to 500 ⁇ g per dose, and more such as between 1 to lOO ⁇ g per dose ( 10, 20, 30, 40, 50, 60, 70, 80 or 90 ⁇ g per dose).
- the amount of CpG or immunoslimulatory oligonucleotides in the adjuvants or vaccines of the present disclosure is generally small, but depending on the vaccine formulation maybe in the region of 1 to lOOO ⁇ g per dose, generally 1 to 500 ⁇ g per dose, and more such as between 1 to lOO ⁇ g per dose (10, 20, 30, 40, 50, 60, 70, 80 or 90 ⁇ g per dose).
- the amount of saponin for use in the adjuvants of the present disclosure may be in the region of 1 to l OOO ⁇ g per dose, generally 1 to 500 ⁇ g per dose, more such as 1 to 250 ⁇ g per dose, and more specifically between 1 to lOO ⁇ g per dose ( 10, 20, 30, 40, 50, 60, 70. 80 or 90 ⁇ g per dose).
- a formulation comprising phosphoantigen and MPL.
- a formulation comprising phosphoantigen and CpG.
- a formulation comprising phosphoantigen and MPL and QS21 .
- a formulation comprising phosphoantigen and MPL and CpG.
- a formulation comprising phosphoantigen and QS21 and CpG.
- a formulation comprising phosphoantigen and MPL, QS21 and CpG.
- the above formulations may optionally comprise an antigcn/immunogcn provided that the antigen or immiinogcn is not specific to F. tiilarensis.
- the phosphoantigen/formulation/composiiion is a vaccine.
- Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Vollcr et al. University Park Press, Baltimore. Maryland. U.S.A.. 1978. Encapsulation within liposomes is described, for example, by Fiillcrton. US 4.235.877.
- the formulation is provided as a formulation for topical administrations including inhalation.
- suitable inhalablc preparations include inhalable powders, metering aerosols containing propel 1 ant gases or inhalablc solutions free from propcllant gases.
- Inhalable powders according to the disclosure containing the active substance may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable excipient.
- These inhalablc powders may include monosaccharides (e.g. glucose or arabinosc), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextranes), polyalcohols (e.g. sorbitol, mannilol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these with one another.
- monosaccharides e.g. glucose or arabinosc
- disaccharides e.g. lactose, saccharose, maltose
- oligo- and polysaccharides e.g. dextranes
- polyalcohols e.g. sorbitol, mannilol, xylitol
- salts e.g. sodium chloride, calcium carbonate
- Particles for deposition in the lung require a particle size less than 10 microns, such as 1 -9 microns suitably from 0. 1 to 5 ⁇ m. particularly preferably from I to 5 ⁇ m.
- the particle size of the active that is the antigen is ol primary importance.
- propellent gases which can be used to prepare the inhalable aerosols are known from the prior art.
- Suitable propellent gases arc selected from among hydrocarbons such as n-propane. n-butane or isobutanc and halohydrocarbons such as chlorinated and/or fluorinatcd derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutanc.
- the abovementioned propellent gases may be used on their own or in mixtures thereof.
- Particularly suitable propellent gases arc halogcnatcd alkanc derivatives selected from among TG U . TG 12. TG 134a and TG227.
- halogcnatcd hydrocarbons TG 134a ( 1 , 1.1 ,2-tctrafluoiOcthanc) and TG227 ( 1 , 1 , 1 ,2,3,3,3- hcptafluoropropanc) and mixtures thereof are preferred according to the invention.
- the propellant-gas-containing inhalable aerosols may also contain other ingredients such as cosolvcnts, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients arc known in the art.
- the propellant-gas-containing inhalable aerosols according lo the invention may contain up to 5 % by weight of active substance. Aerosols according to the invention contain, for example, 0.002 to 5 % by weight. 0.01 to 3 % by weight, 0.01 5 to 2 % by weight, 0. 1 to 2 % by weight, 0.5 to 2 % by weight or 0.5 to I % by weight of active.
- the phosphoantigen is employed in a prime boost regime, as the priming and/or boosting dose.
- Priming in this context refers to priming the immune system for a response, such as V ⁇ 9V ⁇ 2 T cel l proliferation and/activation.
- Boosting refer to increasing or sustaining the immune response of said priming.
- the dose is in the range lpg to lOOO ⁇ g per Kg, such as Ing to 10 ⁇ g per Kg.
- the disclosure provides use of a phosphoantigcn for enhancing protective host immune responses specifically those mediated by V ⁇ 9 ⁇ 2 T cells to enable the host to fight infection with intracellular pathogens such as Francisella tulareiisis.
- the disclosure provides a method of stimulating an immune response to fight Francisella ntlarensi.s infection.
- the bioburden is lowered in vivo after administration of the phosphoantigen of the disclosure.
- PBMCs Peripheral Blood Mononuclear Cells
- Human blood 60ml was collected into BD Vacutaincr CPT® sodium citrate lubes and centrifuged (25min: 1500g (no brake)). Buffy coats were removed, placed in Falcon tubes and centrifuged (300g: I5min). The cell pellet was resuspendcd in IOml medium (RPMI +10% Foetal calf scrum (FCS). 200U/ml penicillin.200 ⁇ g/ml streptomycin and L-glutamine (1OmM)). Cell numbers were counted with trypan blue and centrifuged (300g: I5min).
- IOml medium RPMI +10% Foetal calf scrum (FCS). 200U/ml penicillin.200 ⁇ g/ml streptomycin and L-glutamine (1OmM)
- T cells were isolated from PBMC preparations using human Anli-TCR ⁇ / ⁇ Microbcad Kit (Millcnyi Biotech. UK) according to the method described below.
- the PBMC pellet was resuspendcd in 40 ⁇ l medium and lO ⁇ l anti-TCR ⁇ Hapten-Antibody per IxIO 7 cells, mixed well and refrigerated for lOmin.
- Medium (30 ⁇ l) and MACS anti-hapten microbeads-FITC (20 ⁇ l) per IxIO 7 cells were added to cells and mixed well and refrigerated for I5min. Medium was added to cells and centrifuged (300g: 15min).
- the cell pellet was resuspendcd in 500 ⁇ l medium.
- Media 500 ⁇ l
- Media 500 ⁇ l
- MACS column MS 130-042-201: Miltcnyi Biotcc. UK
- a BD Falcon cell strainer 70 ⁇ m was placed on top of the column and the cell suspension added.
- the cell effluent was collected.
- the column was washed 3 times with medium (500 ⁇ l).
- the column was removed from the magnetic separator and place in a Bijoux.
- Medium (ImI) was added to the column and immediately flushed through using plunger from column kit. This is positive/enriched fraction contained the ⁇ T cells. The number of cells in positive fraction was counted.
- the ⁇ T cell population was cultured in a 24-well plate in medium (RPMI + 10% Foetal calf serum (FCS).200U/ml penicillin. 200 ⁇ g/ml streptomycin and L-glutamine (1OmM)) supplemented with 100U/ml human recombinant intcrleukin-2 (IL-2) (Sigma. UK) and isopcntcnyl pyrophosphonatc (IPP) 3 ⁇ g/ml (Sigma. UK). Additional IL-2 (100 U/ml) was added to cells every 3 days. Cells were removed from wells by gently pipetting and scraping the bottom of the well with the tip to mix and break up cell clumps. Cells were counted and resuspended in ImI fresh medium without antibiotics to the correct cell concentration (IxIO 6 cells/ml). THP-I human monocyte cell line
- the non-adheient human monocytic cell line THP J (ATCC®) (ECACC UK) was giown in RPMI 10% Foetal calf sciurn (FCS) 200U/ml penicillin with oi without 200 ⁇ g/ml sticptomycin and L glutamine (1OmM) all obtained fiom Sigma UK in cell cultuie flasks undei stenle conditions Pnoi to infection THP-I cells weie lemoved fiom cell cultuie flasks and centiifuged (30Og 15mm) Cells weie iesuspended in medium without antibiotics counted and readjusted to iequned cell concenttation (2x10 6 CcI Is/ml) THP-I cells (I ml/well) weie plated into 24 well plates and activated with PMA (phoibol 12-myiistatc 13-acclatc Sigma UK) at a final conccnti
- a viable frozen cultuie of / lulaiensis LVS was thawed and 40ul diops wcic spicad on dned BCGA plates at ACDP containment level 2 Plates weie incubated overnight (37"C WeCOi) Loops of bacte ⁇ al lawn weie taken and placed in PBS to make a cloudy suspension with an OD 430I11n leading of between 02-03 (l-2xl ⁇ 6 cfu/ml)
- a I IO dilution of the suspension was peifoimed pnoi to infection of THP-I to provide an appioximate infection dose of IxIO 1 cfu/ml
- the number of bacteiia ieleased fiom THP-I duiing the infection assay was measured in supeinatants fiom wells containing potified ⁇ T cells oi media alone In the absence of ⁇ T cells 1000- 10000 cfu F tulaiensis LVS /ml weie identified No bacterial giowth was obsei ⁇ ed in supeinatants letneved fiom wells containing ⁇ T cells liom S individuals
- Figure 1 shows human ⁇ T cell mediated killing of / tulaiensis LVS and / tulaiensis SCHU S4 THP-I cells infected with F (IxlC cfu/ml IxIO 6 THP-I) were incubated foi 24 houis in the presence of ⁇ T cells ( ⁇ ) oi media alone ( ⁇ )
- A) Intiaccllulai / tulaiensis LVS lel ⁇ evcd following lysis of cells following infection Data is shown as mean of tiiplicate wells foi each individual (1-6) and any iepeats peifoimed on each individual aie also displayed
- Data is icpiescnlcd as mean of tiiplicate wells for each individual (1-3) Enoi bais iepiesent SD of t
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a phosphoantigen for use as a medicament, particularly in the prophylaxis and/or treatment of infection by Francisella, e.g.
Francisella tularensis: and a pharmaceutical composition comprising such phosphoantigens.
Description
Treatment
The present disclosure relates to phosphoantigens for use in the treatment and/or prophylactic protection against tularemia and pharmaceutical compositions comprising said phosphoantigen for the same.
Francisella tularensis is a small pleomorphic Gram negative coccobacillus which causes the disease tularemia. Tularemia is a zoonotic infection. It circulates in populations of rodents and lagomorphs, and outbreaks in humans often parallel outbreaks in animal populations. However, it is not clear whether these animal species are the true reservoir of the bacterium in the environment. A wide range of arthropod vectors have been implicated in the transmission of tularemia between mammalian hosts including mosquitoes, ticks, and deer flies. These vectors can also transmit the pathogen to man. F. tularensis can also be acquired by contact with, or ingestion of. contaminated material including food and water, and by inhalation of infectious particles. Rural populations and especially those individuals who spend periods of lime in endemic areas such as farmers, hunters, walkers and forest workers are most at risk of contracting tularaemia. Outbreaks associated with contaminated water supplies can involve large numbers of cases, but usually the incidence of the disease is low. These water-associated outbreaks arc mainly caused by subspecies holarctica; subspecies tularensis has never been linked to water-borne infections.
The type and severity of disease is dependent on strain, dose and route of infection. F. tularensis subspecies tularensis and holarctica cause the majority of reported cases, with subspecies tularensis causing the more severe disease of the two. Although tularemia can be a severely debilitating or even fatal disease, especially when caused by F. tularensis subspecies tularensis, many cases of disease caused by lower virulence strains are undiagnosed due to the non-specific nature of the symptoms. The incubation period is 3-5 days normally (range 1 -21 ), and patients develop flu-like symptoms which may be protracted and relapsing if untreated.
Infection through the skin results in ulccroglandular tularemia. This is the most common presentation of the disease and can arise following the bile of an infected vector or through direct contact with the flesh of infected animal. Less commonly, infection can occur through the conjunctiva. This is termed oculoglandular tularemia and arises following direct contamination of the eye. Ingestion of infected meat or water can result in oropharyngeal or gastrointestinal tularemia. Inhalation of F. tularensis results in respiratory or pneumonic tularemia. Respiratory tularemia has been reported in farmers following activities such as making hay, where infectious dusts can be generated. Other high-risk activities in endemic areas are lawn-mowing and bush cutting. For example in Martha's Vineyard, Massachusetts, the majority of investigated cases were respiratory, in landscapes undertaking these types of work. Pneumonia can also arise following hacmatogcnous spread in other forms of tularaemia. Symptoms can be variable and depend on the virulence of the strain involved. Infection with the most highly virulent strains can have a case fatality rate of up to 30% if untreated, but antibiotic therapy has reduced this to around 2%. Presentation can range from a mild pneumonia to an acute infection with high fever, malaise, chills, cough, delirium and
pulse-temperature dissociation. Radiological examination may reveal parenchymal infiltrates, most commonly in one lobe, and hilar lymphadenopathy may be present. The infectious dose required to cause disease by this route is very low.
Tularemia responds well to antibiotic therapy. As described above, the mortality rate of the more acute forms of the disease is reduced significantly if the patient receives suitable antibiotics. Historically aminoglycosides have been drugs of choice. Although cl inically effective, streptomycin is rarely used now due to problems of ototoxicity and nephrotoxicity. Similarly, although chloramphenicol has been used historically for treatment, it would be unlikely to be used as a first choice due to the possibil ity of irreversible effects on haematopoiesis. Gentamicin is a suitable alternative aminoglycoside, and has been used for treatment of pneumonic tularemia. Due to the requirement for parenteral dosing and monitoring of serum levels, aminoglycosides are now only used for the most serious cases. The tetracyclines have been associated with high relapse rates on withdrawal. Doxycycline is effective in treatment of tularemia, but should be avoided for use in young children due to possible effects on developing teeth. Ciprofloxacin has been shown to be highly effective in oral therapy of tularemia, and can be considered the current drug of choice for uncomplicated tularemia. It has shown to be effective in treating tularemia in children, and may be suitable for use in pregnant women.
No licensed vaccine is available for prophylaxis of tularaemia. A live vaccine strain (LVS) was developed in the 1950s, and used extensively to vaccinate at-risk workers under Investigational New Drug Status which resulted in a significant decrease in laboratory acquired infections. Although LVS appears to be effective, there have been problems with the strain, such as reversion to virulence, mixed colony morphology and variable immiinogenicity, and thus the LVS strain has failed to achieve licensing for human use.
Given the debilitating nature of tularemia that no prophylactic treatment/vaccine is available which is suitable for use in the general publ ic and the fact that the disease in some instances is difficult to treat, an effective prophylactic therapy and/or treatment of the disease would be useful.
The present disclosure provides a phosphoanligen for the prophylaxis and/or treatment of tularemia.
Whilst phosphoantigens have been suggested previously as potential adjuvants, there has been no suggestion that such compounds can be used in the treatment of a patient in their own right, that is, it has not been previously suggested that a treatment against any of the pathogens described herein could involve a phosphoantigen in the absence of an antigen, or if an antigen is present, that the antigen is not pharmaceutically active in the prophylaxis and/or treatment of tularemia, or it is not present in sufficient amounts to be pharmaceutically active in the prophylaxis and/or treatment of tularemia. As used herein, "adjuvant" refers to a non- antigenic substance or substantially non-antigenic substance that is used in combination with an antigen for enhancing the immune response against the antigen. The present invention is not intended to cover use of a phosphoantigen as an adjuvant in a medicament, such as a medicament against any of the diseases mentioned herein. As used herein, "treatment" can
mean prophylactic treatment (i.e. pre-lieating) or treatment post-infection with a pathogen of the type disclosed herein. A treatment is considered successful if the symptoms of an infection are ameliorated or prevented. As used herein, "pharmaceutically active" means a substance that has a statistically significant measureablc effect on the material/host to which is administered. As used herein, "antigen specific to the pathogen" refers to an attenuated or avirulent strain of the pathogen or a subunit of the said pathogen that is peculiar to that particular type of pathogen.
Use of phosphoantigens for the treatment of a number of diseases, such as tumours, HIV. malaria and other viral and bacterial infections has been suggested. Clinical trials have been performed in relation to the treatment of tumours. However, there is little or no cl inical support to show any efficacy in other clinical indications.
Surprisingly it seems that treating an individual with phosphoantigcn provides beneficial therapeutic effects in relation to prevention of infection, or amelioration of symptoms after infection with /•'. tularensis.
Thus there is provided a phosphoantigcn for use in the treatment or prophylaxis of F. tularensis including subspecies thereof such as tularensis.
In one aspect there is provided a method of treating a patient in need thereof comprising administering a therapeutically effective amount of a phosphoantigen.
In another aspect there is provided a use of a phosphoantigcn for the manufacture of a medicament for the treatment of infection with F. tularensis.
Most bacteria including F. tularensis produce phosphoantigens as intermediates of the DOXP metabolic pathway. Phosphoantigens are small molecular weight molecules with phosphorylated structures that selectively activate human or non-human primate T cells expressing Vγ9Vδ2 T cell receptor.
Phosphoantigens have been isolated from bacterial species such as TUBag l -4 from M. tuberculosis. Certain other phosphoanligens are known such as BrHPP and IHPP examples 1 and 2 respectively in US application publication No. 2004/0087555. The application relates to compounds of the following formula:
wherein X is a halogen selected from I, Br or Cl, R1 is selected from methyl and ethyl, and Cat+ is a cation, and n is an integer between 2 and 20.
A particularly suitable structure therein is:
OH O O
X — CH2-C (CII2),, — O 1' O P O — R3
Rl O"Cat4 O CaI '
wherein X, R l and Cat+ is as defined above and R3 is selected from:
OH
X — CH2-C (CH2J11
Rl
CH, — O
R l W C (CH2),,
and
CH2=C (CH2J11,
RJ
Below is a table of a number of phosphoantigcns from said application.
MOLECULE
Name Λbbicviation SliucUiie isopentenyl IPP CIb pyiophosphate
CH, C (CH2J2 — OPF
3-(chloromethyl)- CIHl'P CH2CI
3-butanol-l-vl diphosphate CH, C (CH2J2 — OPF
OH
3-(bromomethyl)- BrI-IFP CH1Br
3-bulanol-J-yl diphosphiiie CH., C (CIb)2 — OFF
OH
3-(iodomethyl)-3- IHFF CH2I butanol-J-yl diphosphiiie CH, C (CHx)2 — OFF
OH
3-(bιomomelhvD- ISiHFFl CH2Br
3-bulanol-l-yl tiiphosphate CH, C (CH2J2-OPPP
OH
3-(iodomethvl>3- IHFFI CI-M butanol- 1-yl lripliosphaie CH., C I " (CH2J2 — OFFP
OH α. γ di-3- Ii-BiHIP CI-I2IiI CII2Bi (broniomotliyl)-.3- butanol- l-\l H.,C C (Cl-I2): — (JFPFO -(-CII2J2 — C CII, iiiphosphate on OH α. γ di-3- di-IIlTP CIM Cl-M (iodomclhylJ-3- butanol-J-yl H.,C C r — -(CH2J2 — OPFPO — fCH2J: — C r CH, tiiphosphate
OH OH wherein P is phosphate.
Other compounds explicitly disclosed in the case include: 3-(bromomethyl)-3-butanol-l-yl triphosphate (BrHPPP); 3-(iodomcthyl)-3-butanol-l-yl tiiphosphate (IHPPP); uridine 5'- triphosphate gamma-|3-methyl-3butene-l-yl|; alpha, beta di[3-biOmomethyl-3-butanol-l- yljdiphosphale.
An alternative phosplioantigcn is C-IPP
HIPP;
0 0
H'
0-P-O-P-OH I I
OH OH
HTϊglyIPP
HAngelylPP
A particularly potent phosphoaiitigcn is CHDMAPP:
Certain phosphoantigens are described in published patent application publication number US2008/0207568 (Innate Pharma) which describes certain phosphoantigens of the formula:
CaL+ represents one or more cations m is an integer 1 to 3. B is O, NH, CHF, CFT or CHi or any other isostcric group, W is C-R6 or N,
R7 is a C I -I alky! group or any other isosteric group such as CF^,
R3, R4 and R6 are independently selected from H, Ci -; alky or any other isosteric group such as CFJ, R5 is selected from C2.iacyl. aldehyde, a Ci--* alcohol or a C2.-! ester, and Y=O~Cat+ is as defined therein.
Any suitable phosphoantigen may be employed to for the prophylaxis or treatment of tularemia, including a synthetic and/or natural phosphoantigen. Particularly suitable phosphoantigens arc described above, such as CHDMAPP and IPP, which appear to be very suitable for the treatment of tularemia.
Prophylaxis as employed herein is intended to refer to wherein an individual has a reduced risk of infection i.e. invasion and/or multipl ication with the relevant pathogen compared to an individual who has not had any prophylactic treatment against the relevant pathogen.
In one embodiment there is a reduced risk of developing severe infection, for example caused by subspecies tularensis.
Reduced risk as employed herein refers to a 20. 30. 40, 50, 60, 70, 80% or more reduced risk of developing the infection or a severe form thereof (such as developing the infection).
In one aspect the phosphoantigcns employed arc not compounds of the following formula:
wherein
X is a halogen selected from I, Br or Cl, R1 is selected from mcthy and ethyl, and Cat+ is a cation, and n is an integer between 2 and 20.
In one aspect the phosphoanligen is employed in combination with a cytokine, for example human recombinant inteiieukin-2 (IL-2) which may be co-administered or co-formulated with the phosphoantigcn.
In one embodiment, for example when a patient has been exposed to F. iitlciren.sis or inoculated by the same (or alternatively is going into an area with a high risk of infection) the phosphoantigen or formulation thereof, for example as defined herein, may be employed in combination with an antibiotic treatment, for example selected from aminoglycosides, gentamicin. chloramphenicol, doxycyclinc and ciprofloxacin, particularly ciprofloxacin.
Thus in one aspect, the disclosure provides a method of treating tularemia comprising administering a therapeutically effective amount of the phosphoantigen prophylactically or to a patient infected by F. lularensis.
Innoculation or exposure to the relevant pathogen in the environment is not prophylaxis or treatment with an antigen specific to the pathogen, as employed herein. Nor is it to be considered to be treatment or prophylaxis by administration of a pharmaceutical composition comprising an antigen specific to the pathogen.
In one embodiment the phosphoantigen is administered before infection, for example 1 . 2 or 3 days or a week or a month before exposure.
In one embodiment the phosphoanligen in given shortly after exposure, inoculation or infection, for example I hour to 3 days, such as 2 to 24 hours after.
In one embodiment the phosphoantigen is administered before exposure and shortly after exposure, for example as per the time frames above.
In one embodiment lhe phosphoantigen is employed for the treatment of chronic infection of tularemia.
The in vitro data with the relevant pathogens indicates that the bacterial load in a human monocytic cell line is reduced 10 to 100 fold in the presence of human blood or purified γδ T cells treated with phosphoantigen and human recombinant IL-2 ex vivo. Given that the cells employed in the in vitro assay are retrieved from the blood of healthy individuals' significant confidence can be gained that the phosphoantigcns will work by the same mechanism in vivo.
In one embodiment the disclosure relates to a pharmaceutical composition comprising phosphoantigen in the presence or absence of IL-2, along with a pharmaceutically acceptable excipient for the treatment or prophylaxis of F. tularensis infection. The composition may be employed as described above for the phosphoantigen.
In one embodiment the phosphoantigen is employed in combination with IL-2 and/or a further cytokine such as IL- 15, IL-21 , interferon-γ and/or interferon-α.
The active components of the combinations of the disclosure may, for example, be co- formulated if they arc stable when mixed together. Alternatively, the components may be formulated separately and co-administcrcd. that is administered at the same time or approximately the same time, for example one immediately after the other. In further alternative embodiments the components may be administered sequentially, that is to say with a delay between the administration of each component, for example a delay of I to 1 2 hours.
Formulations
The phosphoantigens or compositions according to the present disclosure maybe administered orally, topically, parenterally, transdermal Iy, as a suppository or by any other pharmaceutically appropriate route.
Typical delivery routes include parenteral administration, e.g., intradermal, intramuscular or by subcutaneous delivery. Other routes include oral administration, intranasal, intravaginal routes, intradermal and transdermal administration.
In one embodiment the phosphoantigen according to the disclosure is provided optionally in cither as a lyophilizcd formulation for rcconstitution later or as a liquid formulation.
Transdermal administration, such as by iontophoresis, may also be an effective method to deliver phosphoanligen to muscle. Epidermal administration may also be employed. Thus the disclosure also extends to delivery by a transdermal patch, which may be occlusive or non- occlusivc.
The actives can also be formulated for administration via the nasal passages. Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 10 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal
passage from a container of the powder held close up to the nose. Suitable formulations wherein the earner is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebulizer, include aqueous or oily solutions of the active ingredient. For further discussions of nasal administration of AIDS-related vaccines, references are made to the following patents, U.S. Pat. Nos. 5,846,978, 5,663. 169. 5,578,597, 5,502,060, 5.476,874, 5,413,999, 5,308,854, 5, 192,668, and 5, 187,074.
Compositions of use in the disclosure include liquid preparations, for an orifice, e.g., oral. nasal, anal, vaginal, etc. administration, such as suspensions, syrups or elixirs: and. preparations for parenteral, subcutaneous, intradermal, intramuscular or intravenous administration (e.g., injectable administration) such as sterile suspensions or emulsions.
In compositions of the disclosure the relevant active ingredient may be in admixture with a suitable earner, diluent, or cxcipicnt such as sterile water, physiological sal ine, glucose or the like.
The active ingredients can be incorporated, if desired, into l iposomes, microspheres or other polymer matrices (Feigner el al., U.S. Pat. No. 5,703,055; Gregoriadis, Liposome
Technology, VoIs. I to III (2nd ed. 1993). each of which is incorporated herein by reference).
Liposomes, for example, which consist of phospholipids or other lipids, arc nontoxic. physiologically acceptable and mctabolizablc carriers that arc relatively simple to make and administer.
Liposome carriers may serve to target a particular tissue or infected cells, as well as increase the half-life of the active. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the vaccine to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to. e.g., a receptor prevalent among lymphoid cells, such as monoclonal antibodies, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired immunogen of the disclosure can be directed to the site of lymphoid cells, where the liposomes then deliver the immunogcn(s). Liposomes may be formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of. e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in. e.g.. Szoka. et al.. Ann. Rev. Biophys. Bioeng. 9:467 ( 1980). U.S. Pat. Nos. 4,235.87 1. 4.501 .728. 4.837.028. and 5.019.369.
The liposomes generally contain a neutral lipid, for example phosphatidylchol ine, which is usually non-crystalline al room temperature, for example egg yolk phosphatidylcholine, dioleoyl phosphatidylcholine or dilauryl phosphatidylcholine.
Optionally the formulation may comprise an adjuvant, for example a known adjuvant formulation may be used to reconstitute the formulation.
Phosphoantigens employed in die disclosure may be mixed or adsorbed with adjuvants, which include but arc not limited to alum, muramyl dipcptidc and saponins such as Quil A. This may further boost the immune system's ability to deal with the infection.
Particular adjuvants are those selected from the group of metal salts, oil in water emulsions. Toll like receptors agonist, (in particular Toll like receptor 2 agonist, Toll l ike receptor 3 agonist, Toll like receptor 4 agonist, Toll like receptor 7 agonist, Toll like receptor 8 agonist and Toll like receptor 9 agonist), saponins or combinations thereof. The level of free antigen in a given formulation may be increased by. for example, formulating the composition in the presence of phosphate ions, such as phosphate buffered saline, or by increasing the ratio of antigen to metal salt. In one embodiment the adjuvant does not include a metal salt as sole adjuvant. In one embodiment the adjuvant does not include a metal salt.
In an embodiment the adjuvant is a Toll like receptor (TLR) 4 ligand, for example an agonist such as a lipid A derivative, in particular monophosphoryl lipid A or more specifically 3- deacylated monophoshoryl lipid A (3D-MPL).
3-Deacylated monophosphoryl lipid A is known from US patent No. 4,912,094 and UK patent application No. 2,220.2 1 1 (Ribi) and is available from Ribi Immunochcm, Montana, USA.
3D-MPL is sold under the trademark MPL® by Corixa Corporation and primarily promotes CD4+ T cell responses with an IFN-g (Th 0 phenotype. It can be produced according to the methods disclosed in GB 22202 1 1 A. Chemically it is a mixture of 3-dcacylatcd monophosphoryl lipid A with 3, 4, 5 or 6 acylatcd chains. Generally in the compositions of the present disclosure small particle 3D-MPL is used. Small particle 3D-MPL has a particle size such that it may be sterile- filtered through a 0.22μm filter. Such preparations are described in International Patent Application No. WO 94/21292.
Synthetic derivatives of lipid A arc known and thought to be TLR 4 agonists including, but not limited to:
OM 174 (2-deoxy-6-O-| 2-dcoxy-2-| (R)-3-dodccanoyloxytctra-dccanoylam ino |-4-o- phosphono-β-D-glucopyranosyl |-2-| (R)-3-hydiOxytetradecanoyl amino |-α-D- glucopyranosyldihydiOgenphosphaie), (WO 95/14026). OM 294 DP (3S, 9 R)-3-|(R)-dodecanoyloxytetradecanoylamino|-4-oxo-5-a/Ja-9(R)- | (R)-3 - hydroxytctradccanoylaminodccan- 1 , 10-diol, l , 10-bis(dihydrogcnophosphatc) (WO 99/64301 and WO 00/0462).
OM 197 MP-Ac DP ( 3S-, 9R) -3-[(R) -dodecanoyloxytetradecanoylaminoJ^-oxo-S- aza-9- [(R)-3 -hydroxytetradecanoylamino] decan- 1 , 10-diol, 1 -dihydrogenophosphate 10-(6- aminohexanoate) (WO 01 /46127).
Typically when 3D-MPL is used the antigen and 3D-MPL arc delivered with alum or presented in an oil in water emulsion or multiple oil in water emulsions. The incorporation of 3D-MPL is advantageous since it is a stimulator of effector T-ccll responses. Alternatively the 3D-MPL may be formulated as liposomes.
Other TLR4 ligands which may be used are alkyl GIucosaminide phosphates (AGPs) such as those disclosed in WO 98/50399 or US 6303347 (processes for preparation of AGPs are also disclosed), or pharmaceutically acceptable salts of AGPs as disclosed in LJS 6764840. Some AGPs are TLR4 agonists, and some are TLR4 antagonists. Both are thought to be useful as adjuvants.
Another immunoslimulant for use in the present disclosure is Quil A and its derivatives. Quil A is a saponin preparation isolated from the South American tree Quilaja Saponaria Molina and was first described as having adjuvant activity by Dalsgaard ct al. in 1974 ("Saponin adjuvants", Archiv. fur die gesamte Virusforschung, Vol. 44, Springer Verlag, Berlin, p243- 254). Purified fragments of Quil A have been isolated by HPLC which retain adjuvant activity without the toxicity associated with Quil A (EP 0 362 278), for example QS7 and QS2 J (also known as QA7 and QA21 ). QS2 I is a natural saponin derived from the bark of Quillaja saponaria Molina which induces CD8+ cytotoxic T cells (CTLs), Thi cells and a predominant IgG2a antibody response.
Particular formulations of QS2 I have been described which further comprise a sterol (WO 96/33739). The ratio of QS21 : sterol will typically be in the order of 1 : 100 to 1 : 1 weight to weight.
Generally an excess of sterol is present, the ratio of QS2 1 :stcrol being at least 1 :2 w/w. Typically for human administration QS2 I and sterol will be present in a vaccine in the range of about 1 μg to about 100 μg. such as about I O μg to about 50 μg per close.
A formulation comprising QS2 I and liposomes may be prepared, for example containing a charged lipid, which increases the stability of the lipsomc-QS2 l structure for liposomes composed of saturated lipids. In these cases the amount of charged l ipid is oflen 1 -20% w/w. such as 5- 10%. The ratio of sterol Io phospholipid is 1 -50% (mol/mol), such as 20-25%. These compositions may contain MPL (3-deacylated mono-phosphoryl l ipid A. also known as 3D-MPL).
The saponins may be separate in the form of micelles, mixed micelles (generally, but not exclusively with bile salts) or may be in the form of ISCOM matrices (EP 0109942), liposomes or related colloidal structures such as worm-like or ring-like multimeric complexes or lipidic/layered structures and lamellae when formulated with cholesterol and lipid, or in the form of an oil in water emulsion (for example as in WO 95/17210). The saponins may often be associated with a metallic salt, such as aluminium hydroxide or aluminium phosphate (WO 98/ 15287).
Usually, the saponin is presented in the form of a l iposome, ISCOM or an oil in water emulsion.
Immunostimulatory oligonucleotides may also be used. Examples of oligonucleotides for use in adjuvants of the present disclosure include CpG containing oligonucleotides, generally containing two or more dinucleotide CpG motifs separated by at least three, more often at least six or more nucleotides. A CpG motif is a cylosine nucleotide followed by a guanine
nucleotide. The CpG oligonucleotides are typically deoxynucleotides. In one embodiment the internucleotide in the oligonucleotide is phosphorodithioatc, or more preferably a phosphorothioate bond, although phosphodiester and other internucleotide bonds are within the scope of the disclosure. Also included within the scope of the disclosure arc oligonucleotides with mixed inlei nucleotide linkages. Methods for producing phosphorothioate oligonucleotides or phosphorodilhioate are described in US5.666. 153, US5,278,302 and WO 95/26204.
Examples of oligonucleotides are as follows: TCC ATG ACG TTC CTG ACG TT (CpG 1826)
TCT CCC AGC GTG CGC CAT (CpG 1758)
ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG
TCG TCG TTT TGT CGT TTT GTC GTT (CpG 2006)
TCC ATG ACG TTC CTG ATG CT (CpG 1668) TCG ACG TTT TCG GCG CGC GCC G (CpG 5456), the sequences may contain phosphorothioate modified internucleotide linkages.
Alternative CpG oligonucleotides may comprise one or more sequences above in that they have inconsequential deletions or additions thereto.
The CpG oligonucleotides may be synthesized by any method known in the art (for example see EP 468520). Conveniently, such oligonucleotides maybe synthesized utilising an automated synthesizer.
Examples of a TLR 2 agonist include pcptidoglycan or lipoprotein. Iinidazoquinolincs, such as Imiquimod and Rcsiquimod arc known TLR7 agonists. Single stranded RNA is also a known TLR agonist (TLR8 in humans and TLR7 in mice), whereas double stranded RNA and poly IC (polyinosinic-polycytidylic acid - a commercial synthetic mimetic of viral RNA) are exemplary of TLR 3 agonists. 3D-MPL is an example of a TLR4 agonist whilst CpG is an example of a TLR9 agonist.
An immunostimulant may alternatively or in addition be included. In one embodiment this immunostimulanl will be 3-deacylated monophosphoryl lipid A (3D-MPL).
Adjuvants combinations include 3D-MPL and QS2 I (EP 0 671 948 Bl), oil in water emulsions comprising 3D-MPL and QS21 (WO 95/ 17210, WO 98/56414), or 3D-MPL formulated with other carriers (EP 0 689 454 Bl) including liposomes. Other adjuvant systems comprise a combination of 3D-MPL, QS2 I and a CpG oligonucleotide as described in US 6558670 and US 6544518.
In one aspect the adjuvant comprises 3D-MPL. In one aspect the adjuvant comprises QS2 1 . In one aspect the adjuvant comprises CpG. In one aspect the adjuvant comprises QS2 I and 3D-MPL. In one aspect the adjuvant comprises QS21 , 3D-MPL and CpG
In one aspect the adjuvant is formulated as an oil in water emulsion.
In one aspect the adjuvant is formulated as liposomes.
The amount of 3D-MPL used is generally small, but depending on the vaccine formulation may be in the region of 1 to l OOOμg per dose, generally 1 to 500μg per dose, and more such as between 1 to lOOμg per dose ( 10, 20, 30, 40, 50, 60, 70, 80 or 90μg per dose).
The amount of CpG or immunoslimulatory oligonucleotides in the adjuvants or vaccines of the present disclosure is generally small, but depending on the vaccine formulation maybe in the region of 1 to lOOOμg per dose, generally 1 to 500μg per dose, and more such as between 1 to lOOμg per dose (10, 20, 30, 40, 50, 60, 70, 80 or 90μg per dose).
The amount of saponin for use in the adjuvants of the present disclosure may be in the region of 1 to l OOOμg per dose, generally 1 to 500μg per dose, more such as 1 to 250μg per dose, and more specifically between 1 to lOOμg per dose ( 10, 20, 30, 40, 50, 60, 70. 80 or 90μg per dose).
Thus in one embodiment there is provided a formulation comprising phosphoantigen and MPL.
In one embodiment there is provided a formulations comprising phosphoantigen and QS2 I .
In one embodiment there is provided a formulation comprising phosphoantigen and CpG.
Thus in one embodiment there is provided a formulation comprising phosphoantigen and MPL and QS21 .
Thus in one embodiment there is provided a formulation comprising phosphoantigen and MPL and CpG.
Thus in one embodiment there is provided a formulation comprising phosphoantigen and QS21 and CpG.
Thus in one embodiment there is provided a formulation comprising phosphoantigen and MPL, QS21 and CpG.
The above formulations may optionally comprise an antigcn/immunogcn provided that the antigen or immiinogcn is not specific to F. tiilarensis.
In one embodiment the phosphoantigen/formulation/composiiion is a vaccine.
Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Vollcr et al. University Park Press, Baltimore. Maryland. U.S.A.. 1978. Encapsulation within liposomes is described, for example, by Fiillcrton. US 4.235.877.
In one embodiment the formulation is provided as a formulation for topical administrations including inhalation.
Suitable inhalablc preparations include inhalable powders, metering aerosols containing propel 1 ant gases or inhalablc solutions free from propcllant gases. Inhalable powders according to the disclosure containing the active substance may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable excipient.
These inhalablc powders may include monosaccharides (e.g. glucose or arabinosc), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextranes), polyalcohols (e.g. sorbitol, mannilol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these with one another. Mono- or disaccharides are preferably used, the use of lactose or glucose, particularly but not exclusively in the form of their hydrates.
Particles for deposition in the lung require a particle size less than 10 microns, such as 1 -9 microns suitably from 0. 1 to 5 μm. particularly preferably from I to 5 μm. The particle size of the active (that is the antigen is ol primary importance).
The propellent gases which can be used to prepare the inhalable aerosols are known from the prior art. Suitable propellent gases arc selected from among hydrocarbons such as n-propane. n-butane or isobutanc and halohydrocarbons such as chlorinated and/or fluorinatcd derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutanc. The abovementioned propellent gases may be used on their own or in mixtures thereof.
Particularly suitable propellent gases arc halogcnatcd alkanc derivatives selected from among TG U . TG 12. TG 134a and TG227. Of the abovementioned halogcnatcd hydrocarbons. TG 134a ( 1 , 1.1 ,2-tctrafluoiOcthanc) and TG227 ( 1 , 1 , 1 ,2,3,3,3- hcptafluoropropanc) and mixtures thereof are preferred according to the invention.
The propellant-gas-containing inhalable aerosols may also contain other ingredients such as cosolvcnts, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients arc known in the art.
The propellant-gas-containing inhalable aerosols according lo the invention may contain up to 5 % by weight of active substance. Aerosols according to the invention contain, for example, 0.002 to 5 % by weight. 0.01 to 3 % by weight, 0.01 5 to 2 % by weight, 0. 1 to 2 % by weight, 0.5 to 2 % by weight or 0.5 to I % by weight of active.
In one embodiment of the disclosure the phosphoantigen is employed in a prime boost regime, as the priming and/or boosting dose. Priming in this context refers to priming the immune system for a response, such as Vγ9Vδ2 T cel l proliferation and/activation. Boosting refer to increasing or sustaining the immune response of said priming.
Whilst not wishing to be bound by theory if the appropriate number of doses is exceeded in a relatively short period of time then it is possible induce anergy in the immune system, which is undesirable and should be avoided.
In the one embodiment the dose is in the range lpg to lOOOμg per Kg, such as Ing to 10 μg per Kg.
In one embodiment the disclosure provides use of a phosphoantigcn for enhancing protective host immune responses specifically those mediated by Vγ9δ2 T cells to enable the host to fight infection with intracellular pathogens such as Francisella tulareiisis.
In one embodiment the disclosure provides a method of stimulating an immune response to fight Francisella ntlarensi.s infection.
In one embodiment the bioburden is lowered in vivo after administration of the phosphoantigen of the disclosure.
EXAMPLES
Materials and methods
Preparation of Peripheral Blood Mononuclear Cells (PBMCs)
Human blood (60ml) was collected into BD Vacutaincr CPT® sodium citrate lubes and centrifuged (25min: 1500g (no brake)). Buffy coats were removed, placed in Falcon tubes and centrifuged (300g: I5min). The cell pellet was resuspendcd in IOml medium (RPMI +10% Foetal calf scrum (FCS). 200U/ml penicillin.200μg/ml streptomycin and L-glutamine (1OmM)). Cell numbers were counted with trypan blue and centrifuged (300g: I5min).
Isolation ofyδ T cells from PBMC preparations γδ T cells were isolated from PBMC preparations using human Anli-TCRγ/δ Microbcad Kit (Millcnyi Biotech. UK) according to the method described below. The PBMC pellet was resuspendcd in 40μl medium and lOμl anti-TCR γδ Hapten-Antibody per IxIO7 cells, mixed well and refrigerated for lOmin. Medium (30 μl) and MACS anti-hapten microbeads-FITC (20 μl) per IxIO7 cells were added to cells and mixed well and refrigerated for I5min. Medium was added to cells and centrifuged (300g: 15min). The cell pellet was resuspendcd in 500 μl medium. Media (500 μl) was added to MACS column (MS 130-042-201: Miltcnyi Biotcc. UK). A BD Falcon cell strainer (70 μm) was placed on top of the column and the cell suspension added. The cell effluent was collected. The column was washed 3 times with medium (500 μl). The column was removed from the magnetic separator and place in a Bijoux. Medium (ImI) was added to the column and immediately flushed through using plunger from column kit. This is positive/enriched fraction contained the γδ T cells. The number of cells in positive fraction was counted.
Culture ofγδ T cells
The γδ T cell population was cultured in a 24-well plate in medium (RPMI + 10% Foetal calf serum (FCS).200U/ml penicillin. 200μg/ml streptomycin and L-glutamine (1OmM)) supplemented with 100U/ml human recombinant intcrleukin-2 (IL-2) (Sigma. UK) and isopcntcnyl pyrophosphonatc (IPP) 3μg/ml (Sigma. UK). Additional IL-2 (100 U/ml) was added to cells every 3 days. Cells were removed from wells by gently pipetting and scraping the bottom of the well with the tip to mix and break up cell clumps. Cells were counted and resuspended in ImI fresh medium without antibiotics to the correct cell concentration (IxIO6 cells/ml).
THP-I human monocyte cell line
The non-adheient human monocytic cell line THP J (ATCC®) (ECACC UK) was giown in RPMI 10% Foetal calf sciurn (FCS) 200U/ml penicillin with oi without 200μg/ml sticptomycin and L glutamine (1OmM) all obtained fiom Sigma UK in cell cultuie flasks undei stenle conditions Pnoi to infection THP-I cells weie lemoved fiom cell cultuie flasks and centiifuged (30Og 15mm) Cells weie iesuspended in medium without antibiotics counted and readjusted to iequned cell concenttation (2x106CcI Is/ml) THP-I cells (I ml/well) weie plated into 24 well plates and activated with PMA (phoibol 12-myiistatc 13-acclatc Sigma UK) at a final conccntiation of lOng/ml and weie incubated overnight (37C WoCOi) lo pioducc an adhcicnt monolayci Media was icmovcd fiom wells pi ioi to infection and ieplaced with fiesh media (900μl) without antibiotics
Giowth of F tulaiensis I VS
A viable frozen cultuie of / lulaiensis LVS was thawed and 40ul diops wcic spicad on dned BCGA plates at ACDP containment level 2 Plates weie incubated overnight (37"C WeCOi) Loops of bacteπal lawn weie taken and placed in PBS to make a cloudy suspension with an OD430I11n leading of between 02-03 (l-2xlθ6 cfu/ml) A I IO dilution of the suspension was peifoimed pnoi to infection of THP-I to provide an appioximate infection dose of IxIO1 cfu/ml
Gi owth of F iiilω en sis SCHU S4 A viable frozen cultuie ol / lulaiensis SCHU-S4 was thawed and 4OuI diops weie spicad on dned BCGA plates All woik with this oiganism was peifoimed at ACDP containment level 3 Loops of bacterial lawn weie taken and placed in PBS to make a cloudy suspension with an OD41OnI,! leading of between 02-03(12\IO6 cfu/ml) A I 10 dilution of the suspension was peifoimed pnoi to infection oi THP-I to piovidc an appioximaic infection dose of IxIO^ cfu/ml
Infection of IHP-I monoknei
F tulcnensis suspension (lOOμl /well) was added to the THP-I monolayei and incubated (30-45min 370C COT) Media was then lemoved and fiesh media without antibiotics (iOOμl) was added Isolated γδ T cells oi media only weie added to the infected THP-I monolayei and incubated in a sealed containei (uith COi packet) in 37°C mcubatoi Ioi 24 h Supcinatanls wcic icmovcd fiom wells following incubation and sloicd at -20"C Ioi luithci baclciiological analysis Cells wcic lyscd using stenle distilled watei (ImI) pipetting up and down seveial times to disiupt cells The lysed cell suspension (lOOμl) was added to PBS (900μl) to pievent fuithei cell lysis Dioplets of the lysed cell suspension stabilised in PBS oi thawed cell cultuie supeinatants (3x20μl) weie placed onto duplicate BCGA plates and incubated foi S days (37°C WoCOo) Viable colonics wcic then counted
Results
Human γδ T cells and giowth of F tulaiensis
The effect of human γδ T cells tieated with IPP+1L-2 on intiacellulai giowth of F tukiiensis LVS was investigated In the absence ol γδ T cells the numbci of intiacellulai baclciia infecting the human monocytic cell line (THP-I) was 1000-10000 / lulaiensis LVS cfu/ml In the picscncc of puiificd human vδ T cells (2\ K)"1 cells/ml) obtained fiom 6 dillcicnl individuals a significant dccicasc in the numbei of intiacellulai bacteiia was obseived (p<0000l) |ANOVA| in compaiison with media only contiols (Figuie IA) No significant diffeiences weie obseived between individuals in then ability to kill / tulaiensis LVS (p=0608) A icduciion in giowth of / lulaiensis SCHU S4 was also obseived
in the piesence of human γδ T cells obtained fiom 3 individuals in comparison with media only controls (Figuie IB)
The number of bacteiia ieleased fiom THP-I duiing the infection assay was measured in supeinatants fiom wells containing puiified γδ T cells oi media alone In the absence of γδ T cells 1000- 10000 cfu F tulaiensis LVS /ml weie identified No bacterial giowth was obsei\ed in supeinatants letneved fiom wells containing γδ T cells liom S individuals
Figure 1 shows human γδ T cell mediated killing of / tulaiensis LVS and / tulaiensis SCHU S4 THP-I cells infected with F
(IxlC cfu/ml IxIO6 THP-I) were incubated foi 24 houis in the presence of γδ T cells (♦) oi media alone (α) A) Intiaccllulai / tulaiensis LVS lelπevcd following lysis of cells following infection Data is shown as mean of tiiplicate wells foi each individual (1-6) and any iepeats peifoimed on each individual aie also displayed B) Intiacellulai F tularensis SCHU S4 letneved following lysis of cells following infection fiom 3 difffeient individuals Data is icpiescnlcd as mean of tiiplicate wells for each individual (1-3) Enoi bais iepiesent SD of tiiplicate wells/individual
Figure 2 shows human γδ T cell mediated contiol of free F tularensis LVS Release of F tulaiensis LVS was investigated in supeinatants fiom THP I cells infected with F tulaiensis (IxIO1 cfu/ml IxIO6THP 1) incubated foi 24houis Individual data showing mean of tiiplicate supeinatants (n=5) in the piesence of γδ T cells (♦) oi media alone (π) Enoi bais iepiesent SD of tiiplicate wells/individual
It is envisaged thai one oi moie embodiment desciibed heiein may be combined, as technically appiopπale In the context of this specification compiismg is to be intcipictcd as including
Aspects of the disclosuie coinpiising ceitain elements aie also intended to extend to alternative embodiments "consisting oi consisting essentially of the lelevant elements
Claims
1. A phosphoaniigen for ihe prophylaxis and/or treatment of tularemia.
2. A phosphoantigen according to claim 1, wherein the phosphoantigen is IPP.
3. A phosphoantigen according to claim 1, where in the phosphoantigen is BrHPP or IHPP.
4. A pharmaceutical composition comprising a phosphoaniigen as recited in any one of claims 1 to 3.
5. The pharmaceutical composition of claim 4, further comprising IL-2.
6. The pharmaceutical composition of either claim 4 or 5 for use in the prophylaxis and/or treatment of tularemia.
7. The pharmaceutical composition of claim 6 wherein the composition does not further comprise an antigen that is pharmaceutically active in the prophylaxis and/or treatment of tularemia.
8. A method of treatment for tularemia comprising administering a therapeutically effective amount of a phosphoantigen prophylactically or as treatment to a patient in need thereof.
9. A method of treatment for tularemia comprising administering a therapeutically effective amount of the pharmaceutical composition of any one of claims 4 to 7 prophylactically or as treatment to a patient in need thereof.
10. Use of the pharmaceutical composition of either claim 4 or 5 in the manufacture of a medicament for the prophylaxis or treatment of tularemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0901411.9 | 2009-01-29 | ||
GBGB0901411.9A GB0901411D0 (en) | 2009-01-29 | 2009-01-29 | Treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010086617A2 true WO2010086617A2 (en) | 2010-08-05 |
WO2010086617A3 WO2010086617A3 (en) | 2010-09-16 |
Family
ID=40469217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/000153 WO2010086617A2 (en) | 2009-01-29 | 2010-01-29 | Treatment |
Country Status (2)
Country | Link |
---|---|
GB (2) | GB0901411D0 (en) |
WO (1) | WO2010086617A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198430B2 (en) | 2002-05-31 | 2012-06-12 | The Secretary Of State For Defence | Immunogenic sequences |
US8609108B2 (en) | 2009-04-14 | 2013-12-17 | The Secretary Of State For Defence | Gamma-glutamyl transpeptidase attenuated Francisella |
US8790910B2 (en) | 2006-07-25 | 2014-07-29 | The Secretary Of State For Defence | Live vaccine strain |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US153A (en) | 1837-03-25 | Peters | ||
US5666A (en) | 1848-07-11 | Machinery for sawing irregular shapes | ||
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
EP0109942A2 (en) | 1982-10-18 | 1984-05-30 | Bror Morein | Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
GB2220211A (en) | 1988-06-29 | 1990-01-04 | Ribi Immunochem Research Inc | Modified lipopolysaccharides |
EP0362278A1 (en) | 1987-06-05 | 1990-04-11 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Autocrine motility factors in cancer diagnosis and management |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
EP0468520A2 (en) | 1990-07-27 | 1992-01-29 | MITSUI TOATSU CHEMICALS, Inc. | Immunostimulatory remedies containing palindromic DNA sequences |
US5187074A (en) | 1990-10-11 | 1993-02-16 | Merck & Co., Inc. | Method of hydroxylation with ATCC 55086 |
US5192668A (en) | 1990-10-11 | 1993-03-09 | Merck & Co., Inc. | Synthesis of protease inhibitor |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5308854A (en) | 1990-06-18 | 1994-05-03 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
WO1994021292A1 (en) | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
WO1995014026A1 (en) | 1993-11-17 | 1995-05-26 | Laboratoires Om S.A. | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
WO1995017210A1 (en) | 1993-12-23 | 1995-06-29 | Smithkline Beecham Biologicals (S.A.) | Vaccines |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5476874A (en) | 1994-06-22 | 1995-12-19 | Merck & Co., Inc. | New HIV protease inhibitors |
US5502060A (en) | 1991-10-23 | 1996-03-26 | Merck & Co., Inc. | HIV protease inhibitors |
WO1996033739A1 (en) | 1995-04-25 | 1996-10-31 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
US5578597A (en) | 1993-10-13 | 1996-11-26 | Merck & Co., Inc. | Combination therapy for HIV infection |
EP0671948B1 (en) | 1992-06-25 | 1997-08-13 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
US5663169A (en) | 1992-08-07 | 1997-09-02 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1998015287A1 (en) | 1996-10-05 | 1998-04-16 | Smithkline Beecham Biologicals S.A. | Vaccines |
WO1998050399A1 (en) | 1997-05-08 | 1998-11-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US5846978A (en) | 1996-05-02 | 1998-12-08 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
WO1998056414A1 (en) | 1997-06-11 | 1998-12-17 | Smithkline Beecham Biologicals S.A. | Oil in water vaccine compositions |
WO1999064301A1 (en) | 1998-06-08 | 1999-12-16 | Sca Emballage France | Fast flattening packaging |
WO2000000462A1 (en) | 1998-06-30 | 2000-01-06 | Om Pharma | Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
WO2001046127A1 (en) | 1999-12-22 | 2001-06-28 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6544518B1 (en) | 1999-04-19 | 2003-04-08 | Smithkline Beecham Biologicals S.A. | Vaccines |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
US20040087555A1 (en) | 1998-09-01 | 2004-05-06 | Institut National De La Sante Et De La Recherche Medicate | Phosphohalohydrins, process for the production thereof and use thereof |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US20080207568A1 (en) | 2005-03-22 | 2008-08-28 | Innate Pharma S.A. | Class of Gamma Delta T Cells Activators and Use Thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1408984T3 (en) * | 2001-07-20 | 2009-02-09 | Bioagency Ag | Organophosphorus compounds to activate gamma / delta T cells |
US20070025960A1 (en) * | 2003-05-16 | 2007-02-01 | University Of Maryland Biotechnology Institute | Bisphosphonates for prophylaxis and therapy against bioterrorism agents |
US20070218086A1 (en) * | 2004-04-26 | 2007-09-20 | Innate Pharma, S.A. | Adjuvant Composition and Methods for Its Use |
WO2006067635A2 (en) * | 2004-12-20 | 2006-06-29 | Innate Pharma S.A. | USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT |
WO2009131730A2 (en) * | 2008-01-31 | 2009-10-29 | University Of Iowa Research Foundation | IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS |
EP2123285A1 (en) * | 2008-05-21 | 2009-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy |
-
2009
- 2009-01-29 GB GBGB0901411.9A patent/GB0901411D0/en not_active Ceased
-
2010
- 2010-01-29 WO PCT/GB2010/000153 patent/WO2010086617A2/en active Application Filing
- 2010-01-29 GB GB1001521A patent/GB2467437A/en not_active Withdrawn
Patent Citations (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5666A (en) | 1848-07-11 | Machinery for sawing irregular shapes | ||
US153A (en) | 1837-03-25 | Peters | ||
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
EP0109942A2 (en) | 1982-10-18 | 1984-05-30 | Bror Morein | Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0362278A1 (en) | 1987-06-05 | 1990-04-11 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Autocrine motility factors in cancer diagnosis and management |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094A (en) | 1988-06-29 | 1990-03-27 | Ribi Immunochem Research, Inc. | Modified lipopolysaccharides and process of preparation |
GB2220211A (en) | 1988-06-29 | 1990-01-04 | Ribi Immunochem Research Inc | Modified lipopolysaccharides |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5308854A (en) | 1990-06-18 | 1994-05-03 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
EP0468520A2 (en) | 1990-07-27 | 1992-01-29 | MITSUI TOATSU CHEMICALS, Inc. | Immunostimulatory remedies containing palindromic DNA sequences |
US5187074A (en) | 1990-10-11 | 1993-02-16 | Merck & Co., Inc. | Method of hydroxylation with ATCC 55086 |
US5192668A (en) | 1990-10-11 | 1993-03-09 | Merck & Co., Inc. | Synthesis of protease inhibitor |
US5502060A (en) | 1991-10-23 | 1996-03-26 | Merck & Co., Inc. | HIV protease inhibitors |
US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
EP0671948B1 (en) | 1992-06-25 | 1997-08-13 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
US5663169A (en) | 1992-08-07 | 1997-09-02 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
WO1994021292A1 (en) | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
EP0689454B1 (en) | 1993-03-23 | 1997-09-10 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
US5578597A (en) | 1993-10-13 | 1996-11-26 | Merck & Co., Inc. | Combination therapy for HIV infection |
WO1995014026A1 (en) | 1993-11-17 | 1995-05-26 | Laboratoires Om S.A. | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
WO1995017210A1 (en) | 1993-12-23 | 1995-06-29 | Smithkline Beecham Biologicals (S.A.) | Vaccines |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5476874A (en) | 1994-06-22 | 1995-12-19 | Merck & Co., Inc. | New HIV protease inhibitors |
WO1996033739A1 (en) | 1995-04-25 | 1996-10-31 | Smithkline Beecham Biologicals S.A. | Vaccines containing a saponin and a sterol |
US5846978A (en) | 1996-05-02 | 1998-12-08 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
WO1998015287A1 (en) | 1996-10-05 | 1998-04-16 | Smithkline Beecham Biologicals S.A. | Vaccines |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
WO1998050399A1 (en) | 1997-05-08 | 1998-11-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
WO1998056414A1 (en) | 1997-06-11 | 1998-12-17 | Smithkline Beecham Biologicals S.A. | Oil in water vaccine compositions |
WO1999064301A1 (en) | 1998-06-08 | 1999-12-16 | Sca Emballage France | Fast flattening packaging |
WO2000000462A1 (en) | 1998-06-30 | 2000-01-06 | Om Pharma | Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
US20040087555A1 (en) | 1998-09-01 | 2004-05-06 | Institut National De La Sante Et De La Recherche Medicate | Phosphohalohydrins, process for the production thereof and use thereof |
US6544518B1 (en) | 1999-04-19 | 2003-04-08 | Smithkline Beecham Biologicals S.A. | Vaccines |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
WO2001046127A1 (en) | 1999-12-22 | 2001-06-28 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
US20080207568A1 (en) | 2005-03-22 | 2008-08-28 | Innate Pharma S.A. | Class of Gamma Delta T Cells Activators and Use Thereof |
Non-Patent Citations (4)
Title |
---|
"New Trends and Developments in Vaccines", 1978, UNIVERSITY PARK PRESS |
DALSGAARD ET AL.: "Archiv. fur die gesamte Virusforschung", vol. 44, 1974, SPRINGER VERLAG, article "Saponin adjuvants", pages: 243 - 254 |
GREGORIADIS: "Liposome Technology", vol. I, III, 1993 |
SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198430B2 (en) | 2002-05-31 | 2012-06-12 | The Secretary Of State For Defence | Immunogenic sequences |
US8790910B2 (en) | 2006-07-25 | 2014-07-29 | The Secretary Of State For Defence | Live vaccine strain |
US8609108B2 (en) | 2009-04-14 | 2013-12-17 | The Secretary Of State For Defence | Gamma-glutamyl transpeptidase attenuated Francisella |
Also Published As
Publication number | Publication date |
---|---|
WO2010086617A3 (en) | 2010-09-16 |
GB2467437A (en) | 2010-08-04 |
GB201001521D0 (en) | 2010-03-17 |
GB0901411D0 (en) | 2009-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4931798B2 (en) | Methods for immune, inflammatory or neuroprotective responses | |
US6552006B2 (en) | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen | |
KR20130122902A (en) | Immunogenic compositions and methods for treating neoplasia | |
US8609108B2 (en) | Gamma-glutamyl transpeptidase attenuated Francisella | |
MX2011003625A (en) | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto. | |
WO2010086617A2 (en) | Treatment | |
Yadagiri et al. | Immunotherapy and immunochemotherapy in combating visceral leishmaniasis | |
US8778356B2 (en) | Vaccine | |
EP4327821A1 (en) | Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c) | |
WO2010086614A1 (en) | Treatment | |
EP1924279A2 (en) | Adjuvanted vaccine | |
Caruso et al. | Vaccination in old age: Challenges and promises | |
US20170298083A1 (en) | New immunostimulatory compounds | |
Konur et al. | Liposome-Encapsulated Adjuvants are Potent Inducers of Antigen-Specific T-Cells in Vivo | |
US20170209447A1 (en) | Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant | |
CA2653226A1 (en) | Liposomes and immunopotentiating compositions containing the same | |
KR20010074413A (en) | Th2 adjuvant including Ovalbumin adsorbed in aluminium hydroxide for treating Behcet's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10703491 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10703491 Country of ref document: EP Kind code of ref document: A2 |